Benzinga | May 11, 2021 06:42AM EDT

Morgan Stanley Initiates Coverage On Akoya Biosciences with Overweight Rating, Announces Price Target of $26

Morgan Stanley analyst Tejas Savant initiates coverage on Akoya Biosciences (NASDAQ:AKYA) with a Overweight rating and announces Price Target of $26.